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In the autumn of 2017 I contacted Gunnar Skov Simonsen to ask him for help to choose a 
topic for my thesis. He connected me with Anne-Sofie Furberg, who ended up being my main 
supervisor, in collaboration with Skov Simonsen. We agreed that my thesis should focus on S. 
aureus carriage and whether we could find a correlation between use of smokeless tobacco 
products and carriage of S. aureus in adolescents. 
The purpose of this thesis is to expand the knowledge of risk factors for nasal and throat 
carriage of Staphylococcus aureus (S. aureus), focusing on smokeless tobacco products which 
are highly prevalent in the Norwegian population, but understudied in relation to human 
health.  
I would like to thank my supervisors Anne-Sofie Furberg and Gunnar Skov Simonsen for 
brilliant help and guidance in the process of writing the thesis. I would also like to thank the 






Staphylococcus aureus (S. aureus) is one of the most potent human bacterial pathogens, yet 
20-30% of us carry this bacterium in our nose as part of our habitual microbiota. Due to its 
infection potential, and the development of multi-resistant strains (MRSA), there has been a 
growing interest in this bacterium in the research environment. If we can identify which 
factors affect carrier status, we may be able to prevent some of the serious infections caused 
by S. aureus. Studies have found association between smoking and S. aureus nasal carriage, 
while data on smokeless tobacco (SLT) have been largely lacking.  
As use of SLT is increasing among adolescents in Norway, it would be interesting to see if 
the use of SLTs influences S. aureus carriage.  
Method 
The study population includes the participants in the Tromsø Study – Fit Futures 1 (TFF1). In 
2010-2011 TFF1 invited all first-year upper-secondary school students 
in Tromsø and Balsfjord to an examination of health and lifestyle. There were 1038 
participants (93% attendance). A total of 457 boys and 445 girls had complete data on 
smokeless tobacco use and two nasal and throat swab cultures with one week interval for the 
assessment of S. aureus carriage. The association between smokeless tobacco use and nasal 
and throat carriage was examined with logistic regression analysis, and odds ratio (OR) for 
nasal and throat carriage was adjusted for known risk factors.  
Results   
Girls who used snuff sometimes or daily, had adjusted OR for S. aureus throat carriage of 
1.59 (95% CI = 1.01-2.50; carriage defined as two positive throat cultures) compared with 
non-users. In analysis of the total study population of girls and boys, snuff use sometimes or 
daily was associated with adjusted OR for S. aureus nasal carriage of 1.48 (95% CI = 1.09-
1.99; carriage defined as one or two positive nasal cultures). In analysis stratified by sex, the 
association was found in girls only, with an adjusted OR of 1.86 (95% CI = 1.18-2.94; 
carriage defined as one or two positive nasal cultures) for S. aureus nasal carriage among 
those who used snuff sometimer or daily. There was no association between snuff use and S. 




We found an association between snuff use and S. aureus nasal and throat carriage among 
adolescents girls. Girls who use snuff sometimes or daily have higher odds for S. aureus 




1.1 Staphylococcus aureus 
Staphylococcus aureus (S. aureus) is a gram-positive coccal bacterium arranged in clusters. 
The word aureus means yellow, and it is named so because of the yellow colour it presents 
when grown on media.    
20-30% of the human population are colonized with S. aureus. The most frequent site of 
colonization is the anterior of the nose – the vestibulum nasi. Other known sites of 
colonization are the throat, the axilla and the perineum. S. aureus will not normally cause 
disease in healthy individuals, but it is known to cause opportunistic infections in 
individuals with particular vulnerability, i.e. weakened immune system.   
S. aureus is one of the most potent human bacterial pathogens and can lead to a series of skin 
and soft tissue infections, but also more invasive and life-threatening infections such as 
endocarditis, pneumonitis and sepsis.(1, 2) Carriers of S. aureus have a higher infection rate 
than those who are not carriers of the bacteria, and the infections are predominantly found to 
be by the same strain of bacteria that colonizes the nose of the infected individual.(2) This 
suggests autoinfection - that one is infected by ones’ own microbiota. For this reason, many 
hospitals have chosen to eradicate nasal colonization with antibiotics or antiseptics prior to 
surgeries and invasive procedures, to prevent postoperative infections.(3) Interestingly 
enough, research show that in the case of bacteremia, nasal carriers of S. aureus have better 
treatment outcome and lower mortality than non-carriers.(4)  
Fighting S. aureus infections is a major clinical challenge, especially with the bacteria strains 
that have developed resistance – commonly known as MRSA (methicillin-resistant S. aureus). 
This has led to a growing interest in S. aureus research – aimed at identifying risk factors that 
affect carrier status.   
Carrier status, naturally, depends both on the ability of the bacteria to colonize humans, as 
well as the hosts ability to eradicate them. Several studies have attempted to map the different 
determinants of human carriage. Well documented factors that affect carriage, are age, sex, 
smoking, BMI, circulating vitamin D level and diabetes mellitus.(5-7) 
1.1.1 Carriage 
S. aureus carriage status has traditionally been divided into three groups: non-carriers, 
intermittent carriers and persistent carriers(8). The culture rule proposed by Nouwen et al 
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states that two qualitative and quantitative nasal swabs taken with a one-week interval 
is sufficient for defining persistent nasal carriage. This combination predicted the persistent S. 
aureus carriage state with a reliability of 93.6% in their validation study.(9) As for 
intermittent carriage, seven or more swab cultures are needed to distinguish intermittent 
carriers from non-carriers.(9)  
This division into non-, intermittent and persistent carriage was challenged in 2009 by a 
study which showed that intermittent and non-carriers share similar S. aureus nasal 
elimination kinetics and anti-staphylococcal antibody profiles.(10) This suggests that a 
reclassification into two carrier groups might be more correct: persistent carriers and others 
(non- or intermittent carriers).   
Most studies of S. aureus, have focused on nasal carriage. Vestibulum nasi is the primary 
niche for S. aureus growth and endogenous inter-individual transmission(8, 11) Nevertheless, 
several more recent studies show a higher prevalence of colonization in the oropharynx 
compared to the nose.(12-14) This suggests that the oropharynx is an important reservoir for 
S. aureus and that the oropharynx might be a more frequent site of colonization than the 
nares.  
This is an important discovery, as many of the topical treatments used to eradicate nasal 
colonization prior to surgery and invasive procedures are unlikely to affect oropharyngeal 
colonization. Colonization of the throat is also associated with more long-term carriage than 
other sites of colonization.(15) The oropharynx seems to be a more protected reservoir for S. 
aureus. Successful decolonization is more difficult to achieve with throat colonization, and 
studies have shown a negative correlation with outcome of treatment when colonized with the 
MRSA in the oropharynx.(16, 17)  
A study from 2009 shows that age is a significant risk factor for oropharyngeal colonization. 
After the age of 30, oropharyngeal colonization decreases, while nasal colonization remains 
stable.(18) This variation by age might explain why the major S. aureus colonization site 
varies between studies. The oropharynx may be the most frequent site of colonization in 
younger individuals, while nasal colonization may be more frequent among older individuals. 
However, several studies that have shown a higher prevalence of oropharyngeal carriage 
compared to nasal carriage were conducted on adults, which supports that oropharynx is the 




1.2 Smokeless tobacco 
1.2.1 Types of smokeless tobacco 
Smokeless tobacco is tobacco that you do not inhale and absorb through the lungs, but rather 
through the oral mucosa of the mouth. There are different kinds of smokeless tobacco. A 
study from 2016 (20) splits smokeless tobacco products into four different groups: A) Loose 
moist snuff, B) Moist snuff in pouches, C) Snus and D) Chewing tobacco (Figure 1).  
 
Figure 1 - Different types of smokeless tobacco (20) 
In this study we will focus on snuff, which includes loose moist snuff, moist snuff in pouches 
and snus (A-C).  
Snuff is a finely ground tobacco product that is sold loose or packaged in pouches. The 
tobacco sold in pouches can be either moist or dry. The snuff is used by putting the snuff 
between the lip and the gum, where the product is absorbed through the oral mucosa.      
1.2.2 Use of smokeless tobacco in Norway 
The use of smokeless tobacco products (SLTs) has been increasing in Norway over the past 
10 years.(21) Data from Statistics Norway show that in the age-group 16-24 years there has 
been an increase in daily users of snuff from 11% in 2008 to 19% in 2018 (Figure 2).(22) 
Lack of knowledge about possible adverse health effects of SLTs may contribute to the 
increasing use among adolescents in Norway. Many may choose SLTs as a “healthier” 




Figure 2 - Chart of daily snuff use in age group 16-24 (22) 
1.2.3 Known health effects of smokeless tobacco 
Use of smokeless tobacco has been viewed by many as a “safer” alternative to smoking.(23) 
Health effects of cigarette smoking have been studied for years, and have well documented 
associated health risks. Assuming that smokeless tobacco might share some of the health 
effects of smoke, one can assume a hypothesis based on the research done on smoking and S. 
aureus carriage. Research has shown a higher prevalence of S. aureus nasal carriage among 
smokers compared to non-smokers.(7) Cessation from smoking improves the innate host 
defense and reduces the incidence of S. aureus nasal colonization.(7) However, some studies 
have reported no association (24) or a lower prevalence of S. aureus nasal carriage in smokers 
as in the Tromsø Staph and Skin Study.(25)  
Research on SLT health effects is scarce compared to the research on smoking. Thus, there 
may be significant negative health effects of SLT use that we are not yet aware of. Still, some 
health effects of SLT use have been documented. Studies show that there is an association 
between use of SLTs and oral, esophageal and pancreatic cancers.(26-30) SLT use is also 
associated with cancers of the respiratory and digestive tract, stomach and cervix, as well as 
ischemic heart disease and stroke.(31, 32)      
In regard to S. aureus, a study from 2016 shows that S. aureus can be found in some of the 
smokeless tobacco products.(20) This suggests that one might actually be colonized with the 
bacteria from using smokeless tobacco products, or at least that smokeless tobacco products 




The aim of this study was to determine whether there is an association between the use of 
smokeless tobacco products (moist loose snuff, moist snuff in pouches and snus) and nasal 
and throat carriage of S. aureus in adolescents attending upper-secondary school in the 
Tromsø region. 
3 Material and methods 
3.1 Study population 
The study population includes participants in The Tromsø Study – Fit Futures 1 (TFF1). In 
2010-2011, TFF1 invited all first-year upper-secondary school students in Tromsø and 
Balsfjord to an examination of health and lifestyle. A total of 1038 boys and girls participated 
(93% attendance).  
The TFF1 participants came to the Clinical Research Unit, University Hospital of North 
Norway, for a half-day visit.(33) Information about family, lifestyle and health was collected 
by a self-administered electronic questionnaire. Trained nurses performed an interview about 
diseases and use of medicine, and a general physical examination. The interview included 
detailed registration of any use of antibiotics the last 24 hours. The examination included 
nasal and throat swab samples, and measurements of blood pressure, heart rate, height, 
weight, percent of body fat, waist and hip circumference and blood analyses such as HbA1c 
and vitamin D. Repeated nasal and throat swab samples and interview about use of antibiotics 
were taken within approx. one week at school. 
In the present study, 36 participants were excluded due to age > 19 years, according to the 
World Health Organization’s definition of adolescents as individuals in the 10-19 years age 
group(34). Furthermore, we excluded 17 participants who had taken antibiotics the last 24 
hours prior to nasal and throat swabbing. As the study aims to test whether smokeless tobacco 
use is associated with S.aureus carriage, we excluded 83 participants with missing values for 
smokeless tobacco use and/or nasal and throat samples. 




Figure 3 - Selection of Study Population 
3.2 S. aureus carriage 
To detect S. aureus carriage repeated swabs from the anterior nares and tonsils were taken; 
the first set of swabs at the screening site and the second set at school one week after. The 
swabs were taken from the anterior nares and the surface of both tonsils with a moist sterile 
brush. The brushes were placed in Amies charcoal transport medium (Copan, Brescia, Italy) 
and analysed by the microbiology laboratory at the University hospital of North Norway 
(UNN) within 24 hours. Selective agar plates and standard laboratory methods were used to 
detect S. aureus and MRSA. All S. aureus isolates were frozen at -70 degrees Celsius. Based 
on the culturing results, the S. aureus phenotype was categorized into three groups: Non-
carriers (two negative swabs), Intermittent carriers (one positive swab), and Persistent carriers 
(two positive swab). In the logistic regression models, we used a dichotomous S. aureus 
variable; “Non- or intermittent carriers” versus “Persistent carriers” in line with the 
reclassification of S. aureus carriage types suggested by van Belkum et al.(10) We also used 
an alternative dichotomization of the S. aureus variable; “Carriers” and “Non-carriers”, where 




3.3 Smokeless tobacco use 
The participants filled in an electronic questionnaire on lifestyle and health. Smokeless 
tobacco use was mapped with the question “Do you use snuff?” and alternatives “No, never”, 
“Yes, sometimes”, “Yes, daily”. It is important to emphasize that in Norway the word “snuff” 
or “snus” is used about both packaged and loose SLTs. Snuff use was recoded into a 
dichotomous variable in the analysis, with categories “Never” and “Sometimes or daily”.  
3.4 Ethics 
The data collection in TFF1 was approved by REK North and the Norwegian Data 
Inspectorate. The present study was approved by REK North.  
All participants signed a declaration when arriving at the study site, and participants younger 
than 16 years had to bring written permission from their guardians. 
3.5 Statistical analysis 
In order to examine whether snuff use is associated with nasal and throat carriage of S. 
aureus, we used descriptive analysis and logistic regression models. Differences in S. aureus 
carriage rates between users (sometimes or daily) and non-users of snuff were tested by chi-
square test. We used logistic regression analysis to estimate odds ratio for S. aureus nasal and 
throat carriage in users of snuff compared to non-users in an age-adjusted model and in 
multivariate model including age and serum vitamin D which is known risk factors for S. 
aureus colonization. In analysis of throat carriage, tonsillectomy was also included in the 
model, while in analysis of nasal carriage, BMI was included. The pattern of S. aureus 
carriage by snuff use differed between girls and boys, and we therefore chose to stratify the 
analysis by sex, even though test for interaction was not statistically significant. All statistical 
analyses were done in SPSS version 25, and the level of statistical significance was set to 
P<0.05.  
4 Results 
The study population in TFF1 consisted of 445 girls and 457 boys. 33.0% of the girls and 
39.4% of the boys used snuff sometimes or daily. The mean age was 16.17 (see Table 1). 
4.1 Snuff use and S. aureus throat carriage 
4.1.1 S. aureus carriage defined as two positive throat cultures 
The prevalence of S. aureus throat carriage for the total study population was 51.2% (carriage 
defined as two positive swabs). Among girls who never use snuff, the prevalence of S. aureus 
throat carriage was 38.6%, while the prevalence among girls who use snuff sometimes or 
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daily was 49.7%. The difference in prevalence was statistically significant (P=0.032, see table 
3). There was no statistically significant difference in prevalence of S. aureus throat carriage 
between boys who never use snuff and boys who use snuff sometimes or daily. 
Logistic regression analysis was used to determine whether there was an association between 
snuff use sometimes or daily and S. aureus oropharyngeal carriage. Girls who used snuff 
sometimes or daily, had an age-adjusted OR for S. aureus throat carriage of 1.57 (95% CI = 
1.05-2.33, see table 5) compared to non-users. The estimate was almost unchanged when 
including tonsillectomy and serum vitamin D in the model, OR=1.59 (95% CI = 1.01-2.50, 
see table 5). There was no significant association between snuff use and S. aureus throat 
carriage among boys. In age-adjusted analysis, the OR for S. aureus throat carriage was 
significantly lower for those who had had a tonsillectomy and significantly higher for those 
with alcohol use once per month or less, both for the total study population and for the girls.  
When stratifying by tonsillectomy, girls without tonsillectomy who used snuff sometimes or 
daily had an OR of 1.82 (95% CI = 1.18-2.84; age-adjusted) compared to non-users. Among 
boys without tonsillectomy who used snuff sometimes or daily OR was 0.88 (95% CI = 0.57-
1.34; age-adjusted). 
4.1.2 S. aureus carriage defined as one or two positive throat cultures 
We repeated the analysis using the alternative definition of S. aureus carriage, where all 
participants with at least one positive culture were included in the carrier group. There was no 
statistically significant association between snuff use sometimes or daily and S. aureus throat 
carriage. The OR for S. aureus throat carriage was significantly higher for boys than for girls, 
and significantly lower for those who had had a tonsillectomy. 
4.2 Snuff use and S. aureus nasal carriage 
4.2.1 S. aureus carriage defined as two positive nasal cultures 
Prevalence rates of persistent S. aureus nasal carriage in the total study population were 
43.3% for non-users of snuff and 50.2% for users, P = 0.047 (Table 7). In sex-specific 
analysis, there were no statistically significant differences in S. aureus rates using the two 
positive cultures critera. 
Logistic regression analysis was used to determine whether there was an association between 
snuff use sometimes or daily and S. aureus nasal carriage. In the total study population, snuff 
use sometimes or daily was associated with an OR for S. aureus nasal carriage of 1.32 (95% 
CI = 1.00-1.73; age-adjusted) compared to non-use, although the risk estimate was not 
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statistically significant in the multivariable logistic regression model. Among girls, there was 
a statistically significantly lower OR for S. aureus nasal carriage associated with BMI. 
4.2.2 S. aureus carriage defined as one or two positive nasal cultures 
The prevalence of S. aureus nasal carriage for the total study population was 59.1% (carriage 
defined as one or two positive swabs). Among those who never used snuff, the prevalence of 
S. aureus nasal carriage was 55.3%, while the prevalence among those who used snuff 
sometimes or daily was 65.7%. The difference in prevalence was statistically significant 
(P=0.002, see table 4). Among girls who never used snuff, the prevalence of S. aureus nasal 
carriage was 49.3%, while the prevalence among girls who used snuff sometimes or daily was 
63.3%. The difference in prevalence was statistically significant (P=0.006, see table 4). 
For snuff use sometimes or daily in the total study population there was an age-adjusted OR 
for S. aureus nasal carriage of 1.55 (95% CI = 1.17-2.05, see table 8). When adjusting for 
serum vitamin D and BMI the OR was 1.48 (95% CI = 1.09-1.99). We found an association 
between snuff use sometimes or daily and S. aureus nasal carriage among girls, with an age-
adjusted OR of 1.76 (95% CI = 1.17-2.65, see table 8) compared to non-use. The estimate was 
almost unchanged when adjusting for serum vitamin D and BMI in the model, OR=1.86 (95% 
CI = 1.18-2.94). Among boys, there was no association between snuff use and risk of S. 
aureus nasal carriage.  
For the total study population, OR of S. aureus nasal carriage was significantly higher for 
boys than girls. Among girls, the OR of S. aureus nasal carriage was significantly higher with 
higher age, and with alcohol use. The OR of S. aureus nasal carriage among girls was 
significantly lower with higher BMI and with higher circulating vitamin D-levels. 
5 Discussion 
In this population-based cross-sectional study, we identified an association between snuff use 
and S. aureus carriage among adolescent girls. Our data show that girls using snuff sometimes 
or daily, have higher risk of both nasal and throat carriage of S. aureus (59% for throat, 86% 
for nasal, see table 5 and 8). When filtering out the girls who have had a tonsillectomy, there 
is 82% higher odds for S. aureus throat carriage among girls who use snuff compared with 
girls who do not use snuff.  
As far as we know, there are no former studies on snuff use and S. aureus nasal or throat 
carriage. However, assuming that smoking and SLTs may share some of the same health 
effects, there is some available research. A study from 2018 showed that smoking cessation is 
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associated with enhanced expression of S. aureus-associated interleukin 1β (IL-1β) and 
granulocyte colony-stimulating factor (G-CSF) in nasal fluids.(7) This suggest that smoking 
is associated with depression of the expression of IL-1β and G-CSF, and therefore has an 
immune-suppressive effect. Smokeless tobacco having similar effects on the immune 
response is contradicted by a study that shows that smokeless tobacco extract (STE) at low 
concentrations enhanced the production of both TNF-α and IL-1β.(35) However, Hasseus et. 
al. showed that water soluble extract from Swedish moist snuff significantly inhibited con A-
stimulated T-cell proliferation induced by accessory cells from rat oral epithelium.(36) This 
suggests that snuff use inhibits immune response. The research is not completely 
unambiguously, and it is hard to come to a definite conclusion regarding the effects of 
smokeless tobacco on the immune response. As our study shows an association between the 
use of smokeless tobacco and higher prevalence of S. aureus colonization, one might assume 
that SLTs in some way inhibits the innate immune response or stimulate adherence and 
growth of the microbe.  
In our study, the association between snuff use and S. aureus carriage was only observed 
among girls. We may only speculate why the same association was not seen among boys. Test 
for statistical interaction was not significant. Male sex is a well-established risk factor for S. 
aureus nasal carriage.(37) It has been hypothesised that sex-steroid hormones play a role in 
regulating the immune response against S. aureus. Interestingly, smoking and smoke 
exposure have been associated with levels of circulating sex-steroids and their binding 
proteins in both women and men.(38) Whether the same association can be found between 
SLTs and circulating sex-steroids is currently unknown. 
It remains unclear whether snuff use or factors associated with snuff use, are the cause of the 
higher prevalence of S. aureus nasal and throat carriage associated with snuff use. However, a 
study from 2016 found that S. aureus could be found in some of the smokeless tobacco 
products.(20) This supports our theory that snuff use may be a risk factor for S. aureus 
carriage. Nevertheless, further research, including prospective data, needs to be done in order 
to establish this as a cause-effect relationship. In the present study, girls who used snuff 
sometimes or regularly had higher mean circulating vitamin D levels, higher prevalence of 
smoking, higher alcohol consume, were less physical active and had higher use of hormonal 
contraceptives (results not presented in tables). These aspects may be included in more 
detailed analysis in the future. 
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Strengths of the study include the high response rate (93% attendance), which may contribute 
to reduce selection bias. We had a large data set with a wide range of information about each 
of the participants, and this made it possible for us to adjust for known risk factors associated 
with S. aureus nasal and throat carriage. The study is population-based and therefore to a 
large degree representative for the general population. It is however conducted on a limited 
age-group, and the results cannot be transferred to other age groups without further research.  
A weakness with this study is that the data on snuff use was self-reported. As it is illegal to 
sell snuff and tobacco products to individuals under the age of 18 in Norway, there may be 
under-reported snuff use. We did not include data on average number of snuff portions per 
week among users of snuff, as we believe these data are afflicted with a lot of uncertainty 
(e.g. broad categories for reporting frequency of snuff use). Thus, we were not able to test for 
dose-response relationship.  
There is always a risk of error when sampling nasal and throat swabs. To eliminate sources of 
error, repeated swabs were taken from both nose and oropharynx by trained personnel. The 
logistic regression analysis was adjusted for known confounding variables (i.e. sex, age, 
tonsillectomy, vitamin D, BMI). However, we cannot rule out that our results are partly due to 
unmeasured confounders. We also chose not to adjust for covariates that were strongly 
correlated with snuff use and not reported as a risk factor for S. aureus carriage; i.e. alcohol 
intake.  
Our findings show a higher risk of colonization by a bacteria capable of causing serious and 
possibly life-threatening infections, among girls who use snuff. This supports the theory that 
there are negative health effects associated with use of SLTs that we may not yet be aware of. 
Our findings is important in relation to educating people on the possible health effects 
associated with using SLTs, and expanding the knowledge of these effects. Studies show that 
SLTs are often used as a “safer” alternative to smoking.(23) As more negative health effects 
of SLT use are discovered, the importance of preventing the use of these products increases. 
Our findings contribute to map the possible determinants of human S. aureus carriage. This is 
useful, as S. aureus infections is a major clinical challenge, and many of the infected 
individuals are autoinfected with their own strain of bacteria. Our findings may offer new 
perspectives for the control of the S. aureus reservoir and prevention of S. aureus disease in 
the population. However, future studies should examine whether there is a cause-effect 
relationship between smokeless tobacco products and S. aureus carriage, including larger 
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Table 1 - Characteristics of Study Population. The Tromsø Study Fit Futures 1. Figures are 
means (standard deviation) and numbers (percent) 
 Total, N=902 Girls, N=445 Boys, N=457 
Age at screening, years 16.2 (0.6) 16.2 (0.6) 16.2 (0.6) 
BMI, kg/m2 22.5 (4.2)  22.5 (4.1) 22.5 (4.3) 
Glycated haemoglobin (%) EDTA whole 
blood  
5.3 (0.3)  5.3 (0.3) 5.3 (0.3) 









































How do you rate your own oral health? 
Good 





















Use of hormonal contraceptives 
Combined contraceptive 
Progesterone contraceptive 











































How often do you drink alcohol? 
Never 
Once per month or less 
2-4 times per month 
2-3 times per week 



















How many alcohol units do you usually 



























Are you actively doing sports or physical 

















If you are actively doing sports or 
physical activity outside school, how 
many hours a week are you active? 
None 
About half an hour 
About 1-1.5 hours 
About 2-3 hours 
About 4-6 hours 




























Main high school program 
Program for Specialization in General 
Studies 































Table 2 - Throat carriage by snuff use 
 
Table 3. S. aureus  throat carriage by snuff use (N and percent in brackets). The Tromsø Study Fit Futures 1, N = 902 














Never 124 (21.6) 165 (28.7) 286 (49.7) .383 81 (27.2) 102 (34.2) 115 (38.6) .213 43 (15.5) 63 (22.7) 171 (61.7) .310 
Sometimes 29 (24.0) 33 (27.3) 59  48.8)  14 (21.5) 21 (32.3) 30 (46.2)  15 (26.8) 12 (21.4) 29 (51.8)  
Daily 35 (17.0) 54 (26.2) 117 (56.8)  16 (19.5) 23 (28.0) 43 (52.4)  19 (15.3) 31 (25.0) 74 (59.7)  
             
Never 124 (21.6) 165 (28.7) 286 (49.7) .496 81 (27.2) 102 (34.2) 115 (38.6) .074 43 (15.5) 63 (22.7) 171 (61.7) .558 
Sometimes or 
Daily 
64 (19.6) 87 (26.6) 176 (53.8)  30 (20.4) 44 (29.9) 73 (49.7)  34 (18.9) 43 (23.9) 103 (57.2)  
  Non- or 
interm.a,b 
Persistentc P-value  Non- or 
interm.a,b 
Persistentc P-value  Non- or 
interm.a,b 
Persistentc P-value 
Never  289 (50.3) 286 (49.7) .186  183 (61.4) 115 (38.6) .063  106 (38.3) 171 (61.7) .382 
Sometimes  62 (51.2) 59 (48.8)   35 (53.8) 30 (46.2)   27 (48.2) 29 (51.8)  
Daily  89 (43.2) 117 (56.8)   39 (47.6) 43 (52.4)   50 (40.3) 74 (59.7)  
             
Never  289 (50.3) 286 (49.7) .240  183 (61.4) 115 (38.6) .032  106 (38.3) 171 (61.7) .379 
Sometimes or 
Daily 
 151 (46.2) 176 (53.8)   74 (50.3) 73 (49.7)   77 (42.8) 103 (57.2)  
 Non-
carriera 
Carrierd  P-value Non-
carriera 
Carrierd  P-value Non-
carriera 
Carrierd  P-value 
Never 124 (21.6) 451 (78.4)  .253 81 (27.2) 217 (72.8)  .288 43 (15.5) 234 (84.5)  .105 
Sometimes 29 (24.0) 92 (76.0)   14 (21.5) 51 (78.5)   15 (26.8) 41 (73.2)   
Daily 35 (17.0) 171 (83.0)   16 (19.5) 66 (80.5)   19 (15.3) 105 (84.7)   
             
Never 124 (21.6) 451 (78.4)  .496 81 (27.2) 217 (72.8)  .131 43 (15.5) 234 (84.5)  .372 
Sometimes or 
Daily 
64 (19.6) 263 (80.4)   30 (20.4) 17 (79.6)   34 (18.9) 146 (81.1)   
aNon-carrier: no growth of S.aureus in the two throat swab cultures 
bIntermittent carrier: growth of S.aureus in one of the two throat swab cultures 
cPersistent carrier: growth of S.aureus in both throat swab cultures 
dCarrier: growth of S.aureus in at least one of the throa swab cultures 
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Table 3 - Nasal carriage by snuff use 
Table 4. S. aureus nasal carriage by snuff use (N and percent in brackets). The Tromsø Study Fit Futures 1, N = 902 































Never 257 (44.7) 69 (12.0) 249 (43.3) .037 151 (50.7) 39 (13.1) 108 (36.2) .082 106 (38.3) 30 (10.8) 141 (50.9) .542 
Sometimes 41 (33.9) 17 (14.0) 63 (52.1)  23 (35.4) 12 (18.5) 30 (46.2)  18 (32.1) 5 (8.9) 33 (58.9)  
Daily 71 (34.5) 34 (16.5) 101 (49.0)  31 (37.8) 16 (19.5) 35 (42.7)  40 (32.3) 18 (14.5) 66 (53.2)  
             
Never  257 (44.7) 69 (12.0) 249 (43.3) 0.008 151 (50.7) 39 (13.1) 108 (36.2) .018 106 (38.3) 30 (10.8) 141 (50.9) .400 
Sometimes or 
Daily 
112 (34.3) 51 (15.6) 164 (50.2)  54 (36.7) 28 (19.0) 65 (44.2)  58 (32.2) 23 (12.8) 99 (55.0)  
  Non- or 
Interma,b 
Persistentc P-value  Non- or 
Interma,b 
Persistentc P-value  Non- or 
Interma,b 
Persistentc P-value 
Never  326 (56.7) 249 (43.3) 0.12  190 (63.8) 108 (36.2) 0.24  136 (49.1) 141 (50.9) 0.54 
Sometimes  58 (47.9) 63 (52.1)   35 (53.8) 30 (46.2)   23 (41.1) 33 (58.9)  
Daily  105 (51.0) 101 (49.0)   47 (57.3) 35 (42.7)   58 (46.8) 66 (53.2)  
             
Never   326 (56.7) 249 (43.3) 0.047  190 (63.8) 108 (36.2) 0.10  136 (49.1) 141 (50.9) 0.39 
Sometimes or 
Daily 
 163 (49.8) 164 (50.2)   82 (55.8) 65 (44.2)   81 (45.0) 99 (55.0)  
 Non-
carriera 
Carrierd  P-value Non-
carriera 
Carrierd  P-value Non-
carriera 
Carrierd  P-value 
Never 257 (44.7) 318 (55.3)  0.009 151 (50.7) 147 (49.3)  0.020 106 (38.3) 171 (61.7)  0.42 
Sometimes 41 (33.9) 80 (66.1)   23 (35.4) 42 (64.6)   18 (32.1) 38 (67.9)   
Daily 71 (34.5) 135 (65.5)   31 (37.8) 51 (62.2)   40 (32.3) 84 (67.7)   
             
Never  257 (44.7) 318 (55.3)  0.002 151 (50.7) 147 (49.3)  0.006 106 (38.3) 171 (61.7)  0.19 
Sometimes or 
Daily 
112 (34.3) 215 (65.7)   54 (36.7) 93 (63.3)   58 (32.2) 122 (67.8)   
aNon-carrier: no growth of S. aureus in the two nasal swab cultures 
bIntermittent carrier: growth of S. aureus in one of the two nasal swab cultures 
cPersistent carrier: growth of S. aureus in both nasal swab cultures 




Table 4 - Associations between snuff use and S. aureus throat carriage – two positive throat cultures defined as carriers (ref. Van Belkum et. al) 
Table 5. Associations between snuff use and S. aureus throat carriage. Odds ratios (OR) and 95% confidence intervals (95% CI) from multivariable logistic 
regression analysis. Observations with two S. aureus positive throat cultures defined as carriers (ref. Van Belkum et. al) The Tromsø Study Fit Futures 1. 
  Total (N=902) Girls (N=445) Boys (N=457) 
  OR* (95% CI) OR** (95% CI) OR* (95% CI) OR** (95% CI) OR* (95% CI) OR** (95% CI) 
Snuff use Non-user 1.0 (ref)  1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
 Sometimes or daily 1.18 (0.90-1.55) 1.10 (0.81-1.49)    1.57 (1.05-2.33) 1.59 (1.01-2.50)  0.83 (0.57-1.22) 0.79 (0.53-1.20) 
Sex Girls 1.0 (ref)  1.0 (ref)     
 Boys 2.05 (1.57-2.68) 2.33 (1.73-3.15)       
Age years 1.03 (0.83-1.29) 1.14 (0.89-1.47)    1.18 (0.86-1.64) 1.15 (0.811.62) 0.96 (0.71-1.30) 1.13 (0.78-1.64) 
BMI kg/m2 1.01 (0.98-1.04)  1.00 (0.95-1.04)  1.02 (0.98-1.07)  
HbA1c % glycated 1.16 (0.75-1.81)  0.95 (0.49-1.84)  1.36 (0.70-2.63)  
25-hydroxyvitamin D nmol/l 1.00 (0.99-1.00) 1.00 (0.99-1.01) 1.00 (0.99-1.01) 1.00 (0.99-1.01) 1.00 (0.99-1.01) 1.00 (0.99-1.01) 
Tonsillectomy No 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
 Yes 0.54 (0.36-0.81) 0.55 (0.36-0.85) 0.48 (0.26-0.89) 0.48 (0.25-0.92) 0.57 (0.32-1.00) 0.62 (0.35-1.12) 
Atopic eczema No 1.0 (ref)  1.0 (ref)  1.0 (ref)  
 Yes 1.19 (0.82-1.74)  1.22 (0.75-2.00)  1.54 (0.81-2.93)  
Hormonal contraceptive No    1.0 (ref)    
 Yes   1.23 (0.83-1.83)    
Smoking Never 1.0 (ref)  1.0 (ref)  1.0 (ref)  
 Sometimes or daily 1.18 (0.86-1.62)  1.23 (0.77-1.95)  1.09 (0.79-1.71)  
Alcohol use Never 1.0 (ref)  1.0 (ref)  1.0 (ref)  
 Once per month or less 1.49 (1.08-2.05)  1.99 (1.21-3.28)  1.47 (0.94-2.31)  
 Two or more times/ month 1.29 (0.91-1.82)  1.62 (0.95-2.76)  1.26 (0.78-2.02)  
Recreational physical  
activity 
 








 2-3 hours/week 0.87 (0.60-1.25)  0.98 (0.58-1.65)  0.85 (0.49-1.47)  
 4-6 hours/week 1.01 (0.72-1.42)  1.11 (0.69-1.79)  1.04 (0.63-1.71)  
 7 hours or more/week 1.08 (0.74-1.57)  0.85 (0.47-1.54)  1.15 (0.69-1.92)  
BMI = body mass index; HbA1c, glycated haemoglobin. 
*Age-adjusted logistic regression model, **Multivariable logistic regression model: Snuff use, Age, Sex, Vitamin D, and Tonsillectomy 




Table 5 - Association between snuff use and S. aureus throat carriage – one or two S. aureus positive throat cultures defined as carriers 
Table 6. Association between snuff use and S. aureus throat carriage. Odds ratios (OR) and 95% confidence intervals (95% CI) from multivariable logistic 
regression analysis. Observations with one or two S. aureus positive throat cultures defined as carriers.  The Tromsø Study Fit Futures 1. 
  Total (N=902) Girls (N=445) Boys (N=457) 
  OR* (95% CI) OR** (95% CI) OR* (95% CI) OR** (95% CI) OR* (95% CI) OR** (95% CI) 
Snuff use Non-user 1.0 (ref)  1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
 Sometimes or daily 1.13 (0.81-1.58) 1.13 (0.78-1.64)    1.45 (0.90-2.33) 1.55 (0.91-2.65)  0.79 (0.48-1.30) 0.81 (0.47-1.40) 
Sex Girls 1.0 (ref)  1.0 (ref)     
 Boys 1.64 (1.19-2.28)  1.80 (1.24-2.60)       
Age years 1.03 (0.78-1.35) 1.20 (0.87-1.66)    1.30 (0.86-1.96) 1.41 (0.91-2.20) 0.84 (0.57-1.22) 0.97 (0.60-1.57) 
BMI kg/m2 0.99 (0.95-1.02)  0.97 (0.92-1.01)  1.01 (0.95-1.07)  
HbA1c % glycated 1.57 (0.87-2.82)  1.20 (0.57-2.52)  2.24 (0.85-5.92)  
25-hydroxyvitamin D nmol/l 1.00 (0.99-1.00) 1.00 (0.99-1.01) 1.00 (0.99-1.01) 1.00 (0.99-1.01) 1.00 (0.99-1.01) 1.00 (0.991.01) 
Tonsillectomy No 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
 Yes 0.53 (0.34-0.82) 0.54 (0.34-0.87) 0.50 (0.28-0.91) 0.50 (0.27-0.93) 0.55 (0.28-1.08) 0.59 (0.29-1.20) 
Atopic eczema No 1.0 (ref)  1.0 (ref)  1.0 (ref)  
 Yes 1.38 (0.84-2.27)  1.36 (0.75-2.47)  1.82 (0.70-4.75)  
Hormonal contraceptive No    1.0 (ref)    
 Yes   1.33 (0.84-2.12)    
Smoking Never 1.0 (ref)  1.0 (ref)  1.0 (ref)  
 Sometimes or daily 1.07 (0.72-1.59)  1.34 (0.76-2.34)  0.82 (0.47-1.44)  
Alcohol use Never 1.0 (ref)  1.0 (ref)  1.0 (ref)  
 Once per month or less 1.22 (0.83-1.80)  1.26 (0.74-2.15)  1.43 (0.80-2.59)  
 Two or more times/ month 1.22 (0.81-1.85)  1.31 (0.74-2.35)  1.26 (0.68-2.31)  
Recreational physical  
activity 
 








 2-3 hours/week 0.98 (0.63-1.53)  1.31 (0.71-2.41)  0.74 (0.38-1.43)  
 4-6 hours/week 1.12 (0.74-1.70)  1.00 (0.59-1.70)  1.63 (0.79-3.38)  
 7 hours or more/week 1.30 (0.80-2.11)  1.29 (0.64-2.59)  1.22 (0.62-2.39)  
BMI = body mass index; HbA1c, glycated haemoglobin. 
*Age-adjusted logistic regression model 




Table 6 - Associations between snuff use and S. aureus nasal carriage - two S. aureus positive nasal cultures defined as carriers (ref. Van -Belkum et al.) 
Table 7. Associations between snuff use and S. aureus nasal carriage. Odds ratios (OR) and 95% confidence intervals (95% CI) from multivariable logistic 
regression analysis. Observations with two S. aureus positive nasal cultures defined as carriers (ref. Van Belkum et al.) The Tromsø Study Fit Futures 1. 
  Total (N=902) Girls (N=445) Boys (N=457) 
  OR* (95% CI) OR** (95% CI) OR* (95% CI) OR** (95% CI) OR* (95% CI) OR** (95% CI) 
Snuff use Non-user 1.0 (ref)  1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
 Sometimes or daily 1.55 (1.17-2.05) 1.48 (1.09-1.99) 1.76 (1.17-2.65)         1.86 (1.18-2.94) 1.31 (0.88-1.94)          1.35 (0.89-2.05) 
Sex Girls 1.0 (ref)  1.0 (ref)     
 Boys 1.54 (1.18-2.02) 1.52 (1.13-2.04)       
Age years 1.20 (0.95-1.50) 1.05 (0.83-1.34) 1.71 (1.19-2.47) 1.19 (0.84-1.69) 0.91 (0.67-1.25)  0.97 (0.70-1.34) 
BMI kg/m2 0.98 (0.95-1.01) 0.97 (0.94-1.00) 0.94 (0.90-0.99) 0.93 (0.88-0.98) 1.01 (0.96-1.05)  1.01 (0.96-1.06) 
HbA1c % glycated 0.90 (0.58-1.41)  0.69 (0.35-1.34)  1.08 (0.58-2.02)  
25-hydroxyvitamin D nmol/l 1.00 (0.99-1.00) 1.00 (0.99-1.01) 1.00 (0.99-1.00) 0.99 (0.98-1.00) 1.01 (1.00-1.02)  1.01 (1.00-1.02) 
Tonsillectomy No 1.0 (ref)  1.0 (ref)  1.0 (ref)  
 Yes 1.00 (0.67-1.50)   1.06 (0.60-1.87)  0.95 (0.53-1.70)  
Atopic eczema No 1.0 (ref)  1.0 (ref)  1.0 (ref)  
 Yes 1.25 (0.85-1.85)    1.46 (0.88-2.42)  1.13 (0.60-2.14)  
Hormonal contraceptive No    1.0 (ref)    
 Yes   1.29 (0.86-1.92)     
Smoking Never 1.0 (ref)  1.0 (ref)  1.0 (ref)  
 Sometimes or daily 1.13 (0.82-1.57)  1.12 (0.70-1.79)  1.14 (0.72-1.81)  
Alcohol use Never 1.0 (ref)  1.0 (ref)  1.0 (ref)  
 Once per month or less 1.29 (0.93-1.78)  1.77 (1.10-2.87)  1.15 (0.73-1.82)  
 Two or more times/ month 1.56 (1.10-2.22)  2.15 (1.27-3.62)  1.35 (0.83-2.20)  
Recreational physical  
activity 
 








 2-3 hours/week 0.75 (0.52-1.09)  0.71 (0.42-1.19)  0.86 (0.49-1.50)   
 4-6 hours/week 0.89 (0.63-1.25)  0.73 (0.46-1.18)  1.23 (0.74-2.06)  
 7 hours or more/week 1.28 (0.86-1.90)  1.09 (0.60-1.98)  1.39 (0.82-2.36)   
BMI = body mass index; HbA1c, glycated haemoglobin. 
*Age-adjusted logistic regression model 




Table 7 - Associations between snuff use and S. aureus nasal carriage - one or two S. aureus positive throat cultures defined as carriers 
 
Table 7. Associations between snuff use and S. aureus nasal carriage. Odds ratios (OR) and 95% confidence intervals (95% CI) from multivariable logistic 
regression analysis. Observations with one or two S. aureus positive nasal cultures defined as carriers.  The Tromsø Study Fit Futures 1. 
  Total (N=902) Girls (N=445) Boys (N=457) 
  OR* (95% CI) OR** (95% CI) OR* (95% CI) OR** (95% CI) OR* (95% CI) OR** (95% CI) 
Snuff use Non-user 1.0 (ref)  1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
 Sometimes or daily 1.55 (1.17-2.05) 1.48 (1.09-1.99) 1.76 (1.17-2.65)         1.86 (1.18-2.94) 1.31 (0.88-1.94)          1.35 (0.89-2.05) 
Sex Girls 1.0 (ref)  1.0 (ref)     
 Boys 1.54 (1.18-2.02) 1.52 (1.13-2.04)       
Age years 1.20 (0.95-1.50) 1.29 (1.01-1.66) 1.71 (1.19-2.47) 1.73 (1.17-2.54) 0.91 (0.67-1.25)  1.03 (0.73-1.45) 
BMI kg/m2 0.98 (0.95-1.01) 0.97 (0.94-1.00) 0.94 (0.90-0.99) 0.93 (0.88-0.98) 1.01 (0.96-1.05)  1.01 (0.96-1.06) 
HbA1c % glycated 0.90 (0.58-1.41)  0.69 (0.35-1.34)  1.08 (0.58-2.02)  
25-hydroxyvitamin D nmol/l 1.00 (0.99-1.00) 1.00 (0.99-1.01) 1.00 (0.99-1.00) 0.99 (0.98-1.00) 1.01 (1.00-1.02)  1.01 (1.00-1.02) 
Tonsillectomy No 1.0 (ref)  1.0 (ref)  1.0 (ref)  
 Yes 1.00 (0.67-1.50)   1.06 (0.60-1.87)  0.95 (0.53-1.70)  
Atopic eczema No 1.0 (ref)  1.0 (ref)  1.0 (ref)  
 Yes 1.25 (0.85-1.85)    1.46 (0.88-2.42)  1.13 (0.60-2.14)  
Hormonal contraceptive No    1.0 (ref)    
 Yes   1.29 (0.86-1.92)     
Smoking Never 1.0 (ref)  1.0 (ref)  1.0 (ref)  
 Sometimes or daily 1.13 (0.82-1.57)  1.12 (0.70-1.79)  1.14 (0.72-1.81)  
Alcohol use Never 1.0 (ref)  1.0 (ref)  1.0 (ref)  
 Once per month or less 1.29 (0.93-1.78)  1.77 (1.10-2.87)  1.15 (0.73-1.82)  
 Two or more times/ month 1.56 (1.10-2.22)  2.15 (1.27-3.62)  1.35 (0.83-2.20)  
Recreational physical  
activity 
 








 2-3 hours/week 0.75 (0.52-1.09)  0.71 (0.42-1.19)  0.86 (0.49-1.50)   
 4-6 hours/week 0.89 (0.63-1.25)  0.73 (0.46-1.18)  1.23 (0.74-2.06)  
 7 hours or more/week 1.28 (0.86-1.90)  1.09 (0.60-1.98)  1.39 (0.82-2.36)   
BMI = body mass index; HbA1c, glycated haemoglobin. 
*Age-adjusted logistic regression model 
**Multivariable logistic regression model: Snuff use, Age, Sex, Vitamin D, and BMI 
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